The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.
暂无分享,去创建一个
Chih-Chiang Tsou | H. Rammensee | S. Stevanović | O. Kohlbacher | T. Brümmendorf | L. Kanz | D. Niederwieser | L. Bichmann | H. Salih | Malte Roerden | Melanie Märklin | R. Klein | A. Nelde | J. Walz | H. Schuster | D. Kowalewski | A. Marcu | M. Schemionek | J. Peper | Tatjana Bilich | M. Neidert | V. Vucinic | Jens Bauer | Maren Lübke | J. Rieth | H. Schuster | V. Vučinić | Annika Nelde
[1] H. Rammensee,et al. Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens: Nothing New in Spite of the Name. , 2018, Cold Spring Harbor perspectives in biology.
[2] S. Stevanović,et al. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry , 2018, Immunology.
[3] Martin C. Müller,et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. , 2018, The Lancet. Oncology.
[4] H. Rammensee,et al. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy , 2018, Acta Neuropathologica.
[5] Oliver Kohlbacher,et al. HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy , 2017, Oncoimmunology.
[6] T. Brümmendorf,et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML , 2018, Leukemia.
[7] Oliver Kohlbacher,et al. The immunopeptidomic landscape of ovarian carcinomas , 2017, Proceedings of the National Academy of Sciences.
[8] C. Carcassi,et al. HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia. , 2017, Leukemia research.
[9] Charles H. Yoon,et al. An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.
[10] D. Scheinberg,et al. Amendment history : Corrigendum ( September 2017 ) A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide / HLA-I antigens , 2019 .
[11] A. Toubert,et al. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study , 2017, Haematologica.
[12] D. White,et al. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. , 2017, Blood.
[13] H. Rammensee,et al. A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and “pan-leukemia” antigens , 2017, Oncotarget.
[14] S. Mustjoki,et al. Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] H. Rammensee,et al. HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy , 2016, Oncoimmunology.
[16] D. Scheinberg,et al. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen , 2016, Leukemia.
[17] P. Thall,et al. PR1 Peptide Vaccine Induces Specific Immunity With Clinical Responses In Myeloid Malignancies , 2016, Leukemia.
[18] M. Mann,et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry , 2016, Nature Communications.
[19] U. Olsson‐Strömberg,et al. Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients , 2016, Leukemia.
[20] George Coukos,et al. Mass spectrometry-based antigen discovery for cancer immunotherapy. , 2016, Current opinion in immunology.
[21] A. Ho,et al. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation , 2016, International journal of cancer.
[22] M. Nielsen,et al. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets , 2016, Genome Medicine.
[23] S. Razavi,et al. Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia , 2015, PloS one.
[24] D. Scheinberg,et al. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1 , 2015, Nature Biotechnology.
[25] Oliver Kohlbacher,et al. The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. , 2015, Blood.
[26] H. Rammensee,et al. Antileukemia T-cell responses in CLL – We don't need no aberration , 2015, Oncoimmunology.
[27] R. Hehlmann,et al. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia , 2015, Leukemia.
[28] L. Jensen,et al. Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation* , 2015, Molecular & Cellular Proteomics.
[29] Andrew R. Jones,et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations , 2014, Nucleic Acids Res..
[30] Deborah Hix,et al. The immune epitope database (IEDB) 3.0 , 2014, Nucleic Acids Res..
[31] A. Kohlmann,et al. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase , 2015, Journal of Cancer Research and Clinical Oncology.
[32] Hans-Georg Rammensee,et al. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL) , 2014, Proceedings of the National Academy of Sciences.
[33] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[34] A. Kohlmann,et al. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status , 2014, Leukemia.
[35] S Walz,et al. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy , 2014, Leukemia.
[36] D. Scheinberg,et al. LYMPHOID NEOPLASIA A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL 1 leukemias , 2014 .
[37] M. Baccarani,et al. Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial. , 2014 .
[38] S. Rosenberg,et al. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.
[39] Andrew R. Jones,et al. ProteomeXchange provides globally co-ordinated proteomics data submission and dissemination , 2014, Nature Biotechnology.
[40] M. Stratton,et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[42] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[43] H. Rammensee,et al. Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer , 2013, Cancer Immunology, Immunotherapy.
[44] Ellen T. Gelfand,et al. The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.
[45] F. Zufall,et al. Mouse urinary peptides provide a molecular basis for genotype discrimination by nasal sensory neurons , 2013, Nature Communications.
[46] S. Mustjoki,et al. Immunomodulatory Effects of Tyrosine Kinase Inhibitors , 2013 .
[47] S. Stevanović,et al. Biochemical large-scale identification of MHC class I ligands. , 2013, Methods in molecular biology.
[48] T. Brümmendorf,et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] K. Döhner,et al. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. , 2012, Blood.
[50] H. Rammensee,et al. Promiscuous survivin peptide induces robust CD4+ T‐cell responses in the majority of vaccinated cancer patients , 2012, International journal of cancer.
[51] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[52] E. Tartour,et al. Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response , 2012, Clinical Cancer Research.
[53] Michal Šmahel,et al. Antigens in chronic myeloid leukemia: implications for vaccine development , 2011, Cancer Immunology, Immunotherapy.
[54] Arnon Nagler,et al. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. , 2011, Blood.
[55] R. Clark,et al. Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive. , 2010, Experimental hematology.
[56] Philippe Rousselot,et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.
[57] S. Mustjoki,et al. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy , 2010, European journal of haematology.
[58] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[59] J. Wolchok,et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. , 2010, Blood.
[60] Manuel Ayala,et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. , 2010, The New England journal of medicine.
[61] Ricardo Pasquini,et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. , 2010, The New England journal of medicine.
[62] D. Scheinberg,et al. Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation. , 2010, Seminars in immunology.
[63] G. Superti-Furga,et al. Charting the molecular network of the drug target Bcr-Abl , 2009, Proceedings of the National Academy of Sciences.
[64] Andrew J. G. Simpson,et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens , 2008, Nucleic Acids Res..
[65] H. Döhner,et al. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. , 2008, Experimental hematology.
[66] M. Schmitt,et al. Leukemia‐associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia , 2008, European journal of haematology.
[67] I. Kawase,et al. WT1 peptide vaccine for the treatment of cancer. , 2008, Current opinion in immunology.
[68] E. Caron,et al. The MHC class I peptide repertoire is molded by the transcriptome , 2008, The Journal of experimental medicine.
[69] M. Rojewski,et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling , 2008, Journal of cellular and molecular medicine.
[70] O. Lund,et al. NetMHCpan, a method for MHC class I binding prediction beyond humans , 2008, Immunogenetics.
[71] A. Alousi,et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. , 2007, Blood.
[72] William Stafford Noble,et al. Semi-supervised learning for peptide identification from shotgun proteomics datasets , 2007, Nature Methods.
[73] H. Rammensee,et al. Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells , 2007, Cancer Immunology, Immunotherapy.
[74] Hans-Georg Rammensee,et al. Distorted Relation between mRNA Copy Number and Corresponding Major Histocompatibility Complex Ligand Density on the Cell Surface*S , 2007, Molecular & Cellular Proteomics.
[75] O. Lantz,et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. , 2005, Blood.
[76] Mathias M Schuler,et al. SYFPEITHI: database for searching and T-cell epitope prediction. , 2007, Methods in molecular biology.
[77] R. Offringa,et al. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes , 2006, Leukemia.
[78] R. Brand,et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). , 2006, Haematologica.
[79] John Sidney,et al. Predicting population coverage of T-cell epitope-based diagnostics and vaccines , 2006, BMC Bioinformatics.
[80] D. Douek,et al. T-Cell Responses Directed against Multiple HLA-A*0201-Restricted Epitopes Derived from Wilms' Tumor 1 Protein in Patients with Leukemia and Healthy Donors: Identification, Quantification, and Characterization , 2005, Clinical Cancer Research.
[81] D. Douek,et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. , 2005, Blood.
[82] A. Tabilio,et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial , 2005, The Lancet.
[83] M. Bevan,et al. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection , 2004, Nature Immunology.
[84] Franca Ronchese,et al. The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. , 2004, Journal of immunological methods.
[85] D. Scheinberg,et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. , 2004, Blood.
[86] Hans-Georg Rammensee,et al. Cutting Edge: Predetermined Avidity of Human CD8 T Cells Expanded on Calibrated MHC/Anti-CD28-Coated Microspheres 1 , 2003, The Journal of Immunology.
[87] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[88] Mark M. Davis,et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. , 2003, The Journal of clinical investigation.
[89] Urs Christen,et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes , 2003, Nature.
[90] L. Fugger,et al. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules , 2000, Leukemia.
[91] S. Soignet,et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. , 2000, Blood.
[92] R. Schreiber,et al. CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ , 1999 .
[93] M. Davis,et al. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. , 1999, Cancer research.
[94] Stephen P. Schoenberger,et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.
[95] K. Tadokoro,et al. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. , 1998, Blood.
[96] D. Accapezzato,et al. Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes , 1996 .
[97] D. Accapezzato,et al. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. , 1996, Leukemia.
[98] J. Melo,et al. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. , 1993, Blood.
[99] H. Rammensee,et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.
[100] P. Nowell,et al. Chromosome studies on normal and leukemic human leukocytes. , 1960, Journal of the National Cancer Institute.